Form 4: Day One Biopharmaceuticals Executive Samuel C. Blackman Reports Stock Transactions
SEC Form 4 Filing
Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, reports the acquisition and disposition of common stock and restricted stock units to cover tax liabilities.
Summary
- On August 15 and 16, 2024, Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
- Blackman acquired shares through the vesting of RSUs and disposed of some shares to cover tax liabilities associated with the RSU settlements.
- Specifically, on August 15, 2024, Blackman acquired 1,187, 1,437, and 6,062 shares of common stock through RSU conversions.
- On August 16, 2024, Blackman sold 2,232 shares at a price of $13.9991 per share to cover tax obligations.
- Following these transactions, Blackman directly owns 1,127,535 shares of common stock and indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC.
- He also holds derivative securities in the form of RSUs, with 78,814 RSUs remaining after the reported transactions.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to executive compensation and tax obligations, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor executive sentiment and potential alignment with company performance.
Comparison to Industry Standards
- Executive compensation packages often include RSUs that vest over time, aligning executive incentives with long-term company performance.
- Selling shares to cover tax liabilities upon RSU vesting is a common practice among executives.
- The size of the transactions is typical for executives at similar-sized biopharmaceutical companies.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal executive compensation adjustments.
Key Dates
| Date | Description |
|---|---|
| 08/15/2024 | Acquisition of common stock through RSU conversions. |
| 08/16/2024 | Sale of common stock to cover tax liabilities. |
| 08/19/2024 | Date of the report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.